Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $38.50.

Several brokerages have commented on ALGS. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a report on Friday, May 29th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Westpark Capital began coverage on shares of Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 target price on the stock. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Lake Street Capital began coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $45.00 target price on the stock.

Institutional Trading of Aligos Therapeutics

Several hedge funds have recently bought and sold shares of ALGS. Woodline Partners LP acquired a new stake in Aligos Therapeutics during the 1st quarter worth approximately $2,602,000. Marshall Wace LLP acquired a new stake in Aligos Therapeutics during the 4th quarter worth approximately $2,504,000. Bank of America Corp DE raised its holdings in Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after buying an additional 216,646 shares during the period. SummitTX Capital L.P. acquired a new stake in shares of Aligos Therapeutics in the fourth quarter valued at approximately $1,299,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Aligos Therapeutics in the fourth quarter valued at approximately $664,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Price Performance

Aligos Therapeutics stock opened at $4.96 on Tuesday. The company’s 50 day simple moving average is $6.49 and its 200 day simple moving average is $7.79. Aligos Therapeutics has a fifty-two week low of $4.80 and a fifty-two week high of $13.69. The firm has a market capitalization of $30.70 million, a price-to-earnings ratio of -0.57 and a beta of 2.25.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, topping the consensus estimate of ($2.29) by $0.08. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $0.25 million. As a group, analysts predict that Aligos Therapeutics will post -7.47 EPS for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.